| Sumario: | Tenofovir alafenamide (TAF, Vemlidy) is a prodrug of tenofovir, which is indicated for the treatment of chronic hepatitis B (HBV) in adults with compensated liver disease. The manufacturer submitted a price of 19.55 per 25 mg tablet, which, at the recommended dose of 25 mg daily, costs 19.55 per patient per day. Another prodrug of tenofovir, tenofovir disoproxil fumarate (TDF), has been marketed in Canada since 2004 and received a Notice of Compliance from Health Canada for the treatment of HBV in 2008. TDF was reviewed by CADTH Common Drug Review (CDR) for this indication in 2008 and received a recommendation for reimbursement for the treatment of chronic hepatitis B (CHB) infection in adult patients with cirrhosis with an HBV DNA concentration above 2,000 IU/mL. TAF was previously reviewed by CDR as a component of three combination products for the treatment of HIV: Descovy, Genvoya, and Odefsey. If TAF-containing regimens were more expensive than similar TDF-containing regimens, CDR recommended that TAF-containing regimens be reimbursed if the cost did not exceed that of similar regimens including TDF.
|
|---|
